Treating melanoma with BIS(THIOHYDRAZIDE AMIDES)
OwnerMartin Williams, Matthew McLeod +1inventors
InventorsMartin Williams, Matthew McLeod, Keizo Koya
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of preventing or delaying the recurrence of melanoma in a subject with bis(thio-hydrazide amides) represented by a formula selected from Structural Formulas (I)-(IX) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these bis(thio-hydrazide amides) and compositions comprising these bis(thiohydrazide)amides and one or more anti-cancer agent.
Claims52
A method of preventing or delaying the recurrence of melanoma in a subject who has been treated for Stage I, II or III melanoma, comprising administering to the subject an effective amount of a compound represented by the following Structural Formula:
- or a pharmaceutically acceptable salt or solvate thereof, wherein:
- Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group;
- R1-R4 are independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring;
- R7-R8 are independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group;
- and
- Z is O or S.
2-15. (canceled)
(canceled)
25-29. (canceled)
(canceled)
33-42. (canceled)
A method of preventing or delaying the recurrence of melanoma in a subject who has been treated for Stage I, II or III melanoma, comprising administering to the subject an effective amount of a compound represented by the following Structural Formula:
- or a pharmaceutically acceptable salt thereof;
- in combination with an effective amount of taxol or taxotere.
A method of treating melanoma in a subject with Stage I, II or III melanoma, comprising administering to the subject an effective amount of a compound represented by the following Structural Formula:
- or a pharmaceutically acceptable salt or solvate thereof, wherein:
- Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group;
- R1-R4 are independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring;
- R7-R8 are independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group;
- and
- Z is O or S.
54-67. (canceled)
(canceled)
77-81. (canceled)
(canceled)
85-94. (canceled)
A method of treating melanoma in a subject with Stage I, II or III melanoma, comprising administering to the subject an effective amount of a compound represented by the following Structural Formula:
- or a pharmaceutically acceptable salt thereof;
- in combination with an effective amount of taxol or taxotere.
Dependencies are inferred from the claim text.